Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Prif Awdur: | Leng, H |
---|---|
Awduron Eraill: | Simon, K |
Fformat: | Traethawd Ymchwil |
Iaith: | English |
Cyhoeddwyd: |
2019
|
Pynciau: |
Eitemau Tebyg
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
gan: Mabilleau, G, et al.
Cyhoeddwyd: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
gan: Adamopoulos, I, et al.
Cyhoeddwyd: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
gan: Mabilleau, G, et al.
Cyhoeddwyd: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
gan: Magetsari, Rahadyan, et al.
Cyhoeddwyd: (2022) -
Maintenance therapy in multiple myeloma
gan: Jean-Luc Harousseau
Cyhoeddwyd: (2009-08-01)